As conventional ECC methods buckle under the pressure of climbing memory error rates, undermining system reliability, ScaleFlux’s innovative approach using list decoding shatters the limitations, offering rapid and efficient correction of complex errors. This disruptive technology not only boosts DRAM reliability and security but also slashes costs by making use of lower-cost DRAM chips viable, paving the way for a more resilient and cost-effective computing infrastructure. ScaleFlux is not just meeting the demands of the future—it’s redefining them.
Arthrosi Therapeutics, Inc., a late-stage biotechnology company developing a potentially best-in-class, highly potent and selective next generation URAT1 inhibitor to reduce serum urate levels, flares and Tophi in patients with gout, today announced the acceptance of two presentations, including one poster tour at the European League Against Rheumatism (EULAR) Congress 2024 meeting, being held in Vienna, Austria on June 12-15.
NeuCyte, Inc. is an innovative biotechnology company focused on developing novel treatments for neurological and neurodegenerative disorders. NeuCyte is working with Dr. Riccardo Barrile who was recently awarded a NIH Common Fund Complement Animal Research In Experimentation (Complement-ARIE), a crowdsourcing competition for innovative ideas on New Approach Methodologies, or NAMs. The Complement-ARIE Challenge prize competition offered $1,000,000 in total prize money to diverse teams with ideas for new ways of using NAMs to conduct basic research, uncover disease mechanisms, and translate knowledge into products and practice.
NEW YORK–(BUSINESS WIRE)–Citcon, the leading global provider for digital payments, is excited to announce a strategic partnership with Cash App Pay and Afterpay. Specifically, the partnership is aimed at empowering e-Commerce businesses with a lineup of payment solutions through Citcon.